Company Overview and News
Today, we learn from Reuters that Greece aims to resolve a long-standing standoff with Canada's Eldorado Gold.
ATHENS (Reuters) - Greece aims to resolve a long-standing standoff with Canada’s Eldorado Gold Corp. over its development plans in the coming weeks, the energy ministry said on Tuesday.
Although the markets have their own logic, highly capitalized gold-mining companies seemingly should belong on any “stocks to buy” list. Thanks to rising geopolitical tensions and soaring trading sentiment, many folks seek safe-haven assets. While gold stocks seemingly offer a viable solution, their overall performance has been unusually disappointing.
Eldorado Gold is deeply undervalued. It trades just for about one quarter of its book value.
All four precious metals witnessed a choppy market on May 15. Gold dropped about 2.1% and closed at $1,288.90 per ounce. This is the lowest level of gold so far this year, and these low levels were last seen in December 2017 for an ~$29.00 decline. The RSI level for gold was 29, which indicates a possible reversion in price.
Gold’s price dipped 0.13% to $1,312.8 per ounce on May 9. The fall in gold was extended for a number of reasons, including a decrease in overall volatility and rising US Treasury rates. We’ll discuss these factors at length in the next few articles.
TORONTO, May 10, 2018 (GLOBE NEWSWIRE) -- QMX Gold Corporation (“QMX” or the “Company”) (TSX:V:QMX) has intersected strong mineralization north of the past producing Bevcon Gold mine, referred to as the North Shear target. As part of QMX’s 23,400 metres (m) winter drilling program, drill hole 17311-17-008 (852m) was completed on the North Shear target, an area to the north of the Bevcon Intrusion and in the hanging wall of the Bevcon Gold mine.
Gold and silver were marginally weak on Monday, May 7, declining 0.04% and 0.13%, respectively. Gold traded at $1,312.20 per ounce. Its RSI level has dropped to 30.0, which hints at a near-term reversal in its price. Its implied volatility remained at 9.1%.
IAMGOLD (IAG) reported its 1Q18 results after the market closed on May 7. IAG reported EPS (earnings per share) of $0.09, beating the consensus estimate by $0.08. Its revenues also beat the consensus estimate by $14.0 million, coming in at $314.5 million.
TORONTO, May 08, 2018 (GLOBE NEWSWIRE) -- Signature Resources Ltd. (TSX-V:SGU) (OTCQB:SGGTF) ("Signature" or the "Company") is pleased to announce that it has appoint Dr. Dimitrios Kostopoulos to its advisory board.
Currently, there are many factors playing on gold prices, some of which are bullish while others are bearish. While bulls are taking cues from the recent geopolitical concerns stoked by trade tensions, the Syria attacks, and the whimsical policies of the current US administration, bears are taking solace from the rising US rate hike expectations.
Usually, precious metal mining companies follow precious metals. Precious metals seem to be in the doldrums over the strength of the US dollar and the Fed’s decision to raise interest rates. The recent slump in demand for haven assets has also affected mining stocks.
During the last month, the market’s unrest had a significant effect on precious metals and miners, leading to increases in their prices. However, the US dollar has strengthened recently, which had a negative impact on precious metals and mining shares. The settling of the market unrest could have also caused a withdrawal of haven bids.
Yamana Gold’s (AUY) valuation multiple has varied widely between 4.3x and 9.8x over the last five years. Valuation multiples signify what investors are willing to pay for a stock based on analyst estimates. Yamana is currently trading at a forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple of 5.6x.
Yamana Gold (AUY) released its 1Q18 earnings yesterday after the market closed. The company missed analysts’ consensus earnings per share (or EPS) estimate of $0.02, reporting adjusted EPS of $0.01. The company has a history of disappointing the markets with its weaker-than-expected results and inconsistent operational results. AUY’s 4Q17 results were also disappointing since the company reported a loss far below analysts’ expectations.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...